Bank of America’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Bank of America’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-216	Closed	-$42	–	8337
2023 Q4	$42	Buy	+216	New	+$47	﹤0.01%	7533
2023 Q1	–	Sell	-18	Closed	-$20	–	8433
2022 Q4	$20	Buy	+18	New	+$27	﹤0.01%	7997
2021 Q4	–	Sell	-121,220	Closed	-$1.21M	–	8795
2021 Q3	$1.21M	Buy	+121,220	New	+$1.21M	﹤0.01%	4896

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Bank of America's BTTX Position: Q1 2024 in Review

Bank of America sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 216 shares — an estimated $42 sold.

Bank of America first reported a position in BTTX in Q3 2021 and held it in 3 quarters. The position peaked at $1.21M in Q3 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

Bank of America reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bank of America sold 216 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $42.
Bank of America first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Bank of America's Better Therapeutics, Inc. Common Stock position peaked at $1.21M in Q3 2021.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.